Evidence map›Paper›PMID 40384592›Full record

ArticleHead & neck2025

Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma.

Arisa Nagano, Takuma Matoba, Daisuke Kawakita, Kiyoshi Minohara, Sho Iwaki, Hiroshi Tsuge, Koji Tsukamoto, Sekai Kikuchi, Satsuki Nakano, Takayuki Murase and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Arisa NaganoDepartment of Otolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takuma MatobaDepartment of Otolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0002-2043-678X
Daisuke KawakitaDepartment of Otolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Kiyoshi MinoharaDepartment of Otolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Sho IwakiDepartment of Otolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0003-1808-6941
Hiroshi TsugeDepartment of Otolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Koji TsukamotoDepartment of Otolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Sekai KikuchiDepartment of Otolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Satsuki NakanoDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takayuki MuraseDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yuichiro TadaDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Shinichi IwasakiDepartment of Otolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Funding

Japan Society for the Promotion of Science (JSPS) 22K09731Japan Society for the Promotion of Science (JSPS) 25K12794
6 · The paper itself

Abstract

backgroundThe NTRK fusion gene is detected in most salivary gland secretory carcinomas. While tropomyosin receptor kinase (TRK) inhibitors are used for various solid tumors with the fusion gene, there are no reports regarding TRK inhibitor use for unresectable parotid gland carcinomas that subsequently shrink and become resectable. Here, we report a case of salivary gland secretory carcinoma in which conversion surgery was performed after TRK inhibitor use.

methodsThe patient was a 33-year-old man with a left parotid gland tumor. Examinations revealed a tumor invading the poststyloid compartment and ETV6-NTRK3 fusion gene expression.

resultsEntrectinib administration shrunk the tumor to a size surgically resectable with an adequate margin. The patient underwent total parotidectomy with left supraomohyoid neck dissection.

conclusionsConversion surgery and TRK inhibitor use were effective against unresectable parotid gland carcinoma with the NTRK fusion gene. The case provides a reference for conversion surgery use for unresectable parotid gland carcinomas.

Indexed as

BenzamidesCarcinomaIndazolesParotid NeoplasmsProtein Kinase InhibitorsAdultETS Translocation Variant 6 ProteinHumansMaleNeck DissectionOncogene Proteins, FusionReceptor, trkCBenzamidesentrectinibETS Translocation Variant 6 ProteinETV6-NTRK3 fusion protein, humanIndazolesOncogene Proteins, FusionProtein Kinase InhibitorsReceptor, trkCconversion surgeryhead and neck cancersalivary gland cancersecretory carcinomaTRK inhibitor

Identifiers

PMID40384592
PMCPMC12541672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.